COLL Stock — Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. (COLL)

Updated October 16, 2026.

COLL is a Stock. Total return is 88.7% over the past 11.4 years, 252.8 points behind SPY at 341.5%.

Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes medicines for pain management and related conditions, with a portfolio including products for chronic pain, opioid-induced constipation, and attention deficit hyperactivity disorder. The company does not currently have an established distribution schedule. Collegium Pharmaceutical may appeal to investors seeking exposure to specialty pharmaceuticals and pain management therapeutics.

COLL performance versus SPY

Price and return data through 2026-10-16.

Total return is 88.7% over the past 11.4 years, 252.8 points behind SPY at 341.5%. Over the past year its total return — price change plus distributions reinvested — is -30.2%. Its deepest 1-year drawdown was 56.8%.

COLL key facts

Asset type

Stock

Asset class

Equity

Inception date

05/07/2015

Distribution frequency

None

Last close

$23.19 (as of 2026-10-16)

Market cap

$718,871,286

Average volume

558643.0

Beta

0.719

Payout ratio

0.0%

P/E ratio

18.26

Forward P/E

3.4329

EPS

$1.27

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

COLL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 56.8%.

Who may consider COLL — and who may not

It is a weaker fit for investors who need monthly cash flow (COLL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on COLL

• All tickers starting with C

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions